Shree ganesh bio-tech (India) Limited has filed its quarterly compliance certificate with stock exchanges, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The submission, dated 06.04.2026, covers the quarter ended 31st March 2026.

Regulatory Compliance Filing

The company submitted the mandatory certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 to multiple stock exchanges including BSE Limited, The Calcutta Stock Exchange Ltd, and Metropolitan Stock Exchange of India Limited.

Certificate Details and Confirmation

Satellite Corporate Services Private Limited, serving as the company's Registrar & Share Transfer Agent, issued the compliance certificate. The certificate confirms adherence to standard regulatory requirements for dematerialization processes.

The key confirmations in the certificate include:

• Securities comprised in certificates have been listed on stock exchanges
• Certificates after due verification have been mutilated and cancelled
• Depository name has been substituted in records as registered owner

Dematerialization Activity Status

For the quarter ended 31st March 2026, the certificate specifically states that no physical share certificates were received for dematerialization. This indicates minimal physical-to-electronic share conversion activity during Q4FY26.

Stock Exchange Communications

The filing was submitted to three stock exchanges where the company maintains listings, ensuring comprehensive regulatory compliance across all trading platforms. The company's registered office is located in Kolkata, with corporate identification number L70101WB1982PLC121196.

This quarterly submission represents standard regulatory practice, demonstrating the company's commitment to maintaining transparency in share transfer and dematerialization processes as required by SEBI regulations.

Shree ganesh bio-tech (India) Limited announced its unaudited standalone financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved these results during their meeting held on January 29, 2026, at the company's registered office in Kolkata.

Quarterly Financial Performance

The company's financial performance for Q3FY26 showed mixed results compared to the previous year. Revenue from operations declined significantly while the company maintained profitability during the quarter.

Nine-Month Performance Analysis

For the nine months ended December 31, 2025, Shree Ganesh Bio-Tech (India) Limited reported revenue from operations of ₹284.92 lakh compared to ₹1,995.18 lakh in the corresponding period of the previous year. The company achieved a net profit after tax of ₹66.34 lakh for the nine-month period, compared to ₹133.29 lakh in the previous year.

Cost Structure and Expenses

The company's cost structure showed significant changes during the quarter. Cost of materials consumed was ₹66.08 lakh in Q3FY26 compared to ₹1,375.91 lakh in Q3FY25. Employee benefit expenses increased to ₹7.35 lakh from ₹6.23 lakh in the corresponding quarter of the previous year.

Key Financial Highlights

The company maintained its paid-up equity share capital at ₹3,986.24 lakh with a face value of ₹1.00 per share. Basic and diluted earnings per share for Q3FY26 stood at ₹0.01, compared to ₹0.02 in Q3FY25. For the nine-month period, both basic and diluted earnings per share were ₹0.02.

Board Meeting Details

The Board of Directors meeting commenced at 3:30 PM and concluded at 4:00 PM on January 29, 2026. The unaudited financial results were reviewed by the Audit Committee and subsequently approved by the Board of Directors. The statutory auditors conducted a limited review of the results, which were prepared in accordance with Indian Accounting Standards.